©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Isoleukotrienes Are Biologically Active Free Radical Products of Lipid Peroxidation (*)

(Received for publication, April 24, 1995)

Kathleen A. Harrison , Robert C. Murphy (§)

From the National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

The free radical oxidation of arachidonic acid esterified to glycerophospholipids is known to generate complex metabolites, termed isoprostanes, that share structural features of prostaglandins derived from prostaglandin H synthase. Furthermore, certain isoprostanes have been found to exert biological activity through endogenous receptors on cell surfaces. Using mass spectrometry and ancillary techniques, the free radical oxidation of 1-hexadecanoyl-2-arachidonoyl-glycerophosphocholine was studied in the search for products of arachidonic acid isomeric to the leukotrienes that are derived from 5-lipoxygenase-catalyzed metabolism of arachidonic acid. Several conjugated triene metabolites were chromatographically separated from known 5-lipoxygenase products and structures characterized as 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid esterified to the glycerophosphocholine backbone. We have termed these products as B-isoleukotrienes. Following saponification some, but not all, B-isoleukotrienes were found to exert biological activity in elevating intracellular calcium in Indo-1-loaded human polymorphonuclear leukocytes. This activity could be blocked by a leukotriene B receptor antagonist. An EC of approximately 30 nM was determined for one unique B-isoleukotriene with a relative retention index of 2.54. We have shown that free radical processes can lead to the formation of biologically active isoleukotrienes in glycerophosphocholine liposomes, and we propose that B-isoleukotrienes may also be formed in membrane glycerophospholipids as a result of lipid peroxidation during tissue injury. Such B-isoleukotrienes could then mediate events of tissue damage through activation of leukotriene B receptors on target cells.


INTRODUCTION

Oxygen free radicals are generated in vivo by a variety of enzymatic and nonenzymatic reactions(1, 2, 3) . These reactive oxygen species are thought to play an important role in tissue damage characteristic of many diseases including atherosclerosis, inflammatory diseases, cancer, aging, and ischemia reperfusion injury(4, 5, 6) . While the exact biochemical mechanisms relating free radical generation to the pathology are unclear, most points of view consider profound alterations in tissue biochemistry as a result of lipid peroxidation, DNA damage, or irreversible alteration of proteins(7, 8, 9, 10, 11) . Although lipid peroxidation leads to a large number of products, some of which are stable species derived from polyunsaturated fatty acyl substituents of phospholipids in membrane bilayers, the measurement of low molecular weight products such as pentane, malonyldialdehyde, and 4-hydroxynonenal have been the most widely measured oxidation products for studies of lipid peroxidation(12, 13) . It is likely, however, that these low molecular weight products result from extensive rearrangement of the initial oxidized phospholipid species and, as such, may not reflect initial oxidation events taking place at the lipid bilayer membrane level.

Recently compounds that are isomeric to prostaglandins (isoprostanes) were discovered to be generated by free radical-mediated processes and whose formation was not catalyzed by the enzyme prostaglandin H synthase(14, 15) . F-isoprostanes (isomeric of prostaglandin F) were readily identified esterified to phospholipids in the liver of rats that had been treated with carbon tetrachloride in a model of free radical hepatotoxicity(16) . One such free radical product, 8-epi prostaglandin F was also found to have significant biological activity as the free acid. This isoprostane was found to cause a potent constriction of the renal artery of the rat and reduced glomerular filtration rate in the rat kidney(17) . It was also found to have activity in other organs including the lung, where it constricted the pulmonary artery, but was a more potent constrictor of the bronchial airway in the isolated perfused lung(18) . Interestingly, these biological activities could be prevented or even reversed by a thromboxane A receptor antagonist(17) , suggesting that this F-isoprostane was exerting its pharmacological effect through the endogenous receptor for thromboxane. These findings have led to the suggestion that isoprostanes may serve as lipid mediators of free radical-induced damage at the tissue level(15, 17) .

Since the nonenzymatic, free radical-induced formation of F-isoprostanes in vivo result from a free radical attack on arachidonoyl-containing phospholipids in vivo, it became of interest to investigate whether or not other complex molecules esterified to phospholipids could be formed by free radical reactions, in particular complex molecules structurally related to the leukotrienes. Leukotrienes are normally thought to be derived only from the 5-lipoxygenase pathway of arachidonic acid metabolism. To clarify whether or not such compounds could be formed, we investigated the free radical oxidation 1-hexadecanoyl-2-arachidonoyl-glycerophosphocholine liposomes and report that hydroxyl radical generated by a modified Fenton reaction (19) led to the formation of numerous products including several isomers of leukotriene B (isoleukotrienes) that exhibited biological activity via the leukotriene B receptor.


EXPERIMENTAL PROCEDURES

Materials

Leukotriene B and other eicosanoid standards were purchased from Cayman Chemical Co. (Ann Arbor, MI) and used without further purification. 1-Hexadecanoyl-2-arachidonoyl glycerophosphocholine was purchased from Avanti Polar Lipids (Alabaster, AL). Radiolabeled 1-hexadecanoyl-2[C]arachidonoyl glycerophosphocholine (57 mCi/mmol) was purchased from DuPont NEN. The LTB receptor antagonist LY223982 was a kind gift from Eli Lilly. All solvents used were of the highest available purity. Hydrogen peroxide (30%, w/v), copper(II) chloride, digitonin, ammonium acetate, EGTA, Trizma (Tris base), and phosphate-buffered saline tablets were purchased from Sigma or Aldrich. Sepralyte octadecylsilyl solid phase extraction packing material (40 µm) was purchased from Analytichem International (Harbor City, CA). Pentafluorobenzyl bromide, diisopropylethylamine, and 5% rhodium adsorbed on alumina powder were purchased from Aldrich. Bis-trimethylsilyl trifluoroacetamide was purchased from Supelco (Bellefonte, PA). Indo-1 acetoxymethyl ester was obtained from Calbiochem.

Free Radical Oxidation of 1-Hexadecanoyl-2-arachidonoyl-GPCho

Ten micromoles of 1-hexadecanoyl-2-arachidonoyl-GPCho() in CHCl solution (10 mg/ml) was placed in an 8-ml screw cap glass tube. 1-Hexadecanoyl-2[C]arachidonoyl-GPCho (5 µCi) was also added to some reactions. The solvent was evaporated at room temperature under a stream of N gas. The phospholipid was immediately resuspended in 4.8 ml of 50 mM PBS, pH 7.3, by vortexing and then sonicating for 5 s at maximum power. HO (30%, w/v), and 6 mM CuCl were added to the solution resulting in final concentrations of 600 mM and 100 µM, respectively. The solution was capped and heated to 37 °C on a gently shaking water bath for 3 h. For some experiments reactions were allowed to continue at 5 °C overnight before extraction. Progress of oxidation was monitored by UV absorbance at 235 nm for conjugated dienes and 270 nm for conjugated trienes in a 0.1% aliquot.

Solid Phase Extraction

The reaction mixture was loaded onto 2 g of reverse phase 40-µm silica particles packed in a low pressure glass column. The column was preconditioned with 30 ml of methanol followed by 30 ml of PBS under slight pressure. Salts and remaining HO were eluted with 30 ml of water. Oxidized GPCho was eluted with 15 ml of methanol into a 50-ml pear-shaped flask. The remaining 1-hexadecanoyl-2-arachidonoyl-GPCho was eluted with an additional 10 ml of methanol.

Stannous Chloride Reduction

Hydroperoxides or endoperoxides formed during the oxidation reaction were reduced with stannous chloride to prevent further rearrangement and degradation of these products. Stannous chloride (100 mM) was added to the methanol fraction containing the oxidized GPCho to a final concentration of 1 mM. The flask was placed on a rotary evaporator and the solvent removed to near dryness. The remaining liquid in the flask was rinsed into a test tube (1 ml) and injected directly onto the reverse-phase HPLC system.

Reverse Phase HPLC of Oxidized GPCho

A Beckman (Berkeley, CA) ODS 5-µm 4.6 mm 25-cm column with a Waters (Marlborough, MA) ODS Guard-pak precolumn was used to separate the oxidized GPCho. The solvent system (system A) consisted of 85% methanol, 1 mM ammonium acetate at 1.5 ml/min for 25 min, followed by a linear gradient to 100% methanol, 1 mM ammonium acetate over a 50-min period. Either a photodiode array detector (Hewlett-Packard 1090A) or a linear 206 scanning UV detector (Linear Instruments, Reno, NV) were used to continuously record UV spectra, scanning from 205 nm to 320 nm with a 1-nm step size. A fraction collector was used to collect effluent at 1-min intervals. For those experiments in which radiolabeled 1-hexadecanoyl-2-arachidonoyl GPCho was used, 10% of the oxidized GPCho products were separated on HPLC with a Flo-One Beta (Radiomatic, Riviera Beach, FL) radiochromatography detector connected to the effluent stream after the UV detector.

Electrospray Ionization Mass Spectrometry

Reverse phase HPLC fractions containing the conjugated triene chromophore were analyzed using electrospray ionization (ESI) mass spectrometry and tandem mass spectrometry. Flow injection was used to introduce 2 µl of the HPLC fractions at a flow rate of 10 µl/min with 85% methanol, 1 mM ammonium acetate as the mobile phase. The Sciex API III (Perkin-Elmer Sciex, Toronto, Canada) was operated in negative ion mode with an orifice voltage of -105 V in order to collisionally decompose the GPCho acetate adducts to [M - 15] ions. Product ion spectra were obtained using a collision energy of 30 eV and collision gas thickness (argon) of 220 10 molecules/cm. Negative ion ESI mass spectra of the oxidized fatty acids obtained from hydrolysis of the oxidized GPCho were obtained using an orifice voltage of -60 V. For all ESI analyses, the curtain gas flow was 1.2 liter/min, the nebulizer pressure was 40 p.s.i., the turbospray flow was 7 liters/min, and the turbospray temperature was 400 °C.

Saponification of Oxidized GPCho and Reverse Phase HPLC

Fractions from the first HPLC separation (system A) identified as containing components with a conjugated triene chromophore were saponified by addition of 0.5 ml of 1 N sodium hydroxide at room temperature for 1 h. The fractions were then acidified with 50 µl of 88% formic acid, and the methanol evaporated under vacuum. The fractions were reconstituted in 1 ml of 30% methanol, 70% water (0.05% acetic acid), pH 5.7, for injection into the HPLC system. Spectra of peaks eluting from the Beckman ODS 5-µm 4.6 mm 25-cm column with a Waters ODS Guard-pak precolumn were continuously collected using a photodiode array detector. The HPLC was operated with a three-step gradient (system B) starting at 40% B and ramping to 55% B in 6 min, then to 61% B in 15 min, and to 100% B in 5 min, where B = methanol:acetonitrile (35:65) and A = 0.05% acetic acid, adjusted to pH 5.7 with ammonium hydroxide. The flow rate was 1 ml/min, and fractions were automatically collected at 0.5 min/tube. The elution of each component relative to prostaglandin B and LTB external standards was calculated by the following equation for relative retention index (RRI).

HPLC analysis of the external standards was run immediately after the analysis of oxidized eicosanoids.

Measurement of Intracellular Calcium Levels

Changes in neutrophil intracellular calcium levels were determined by measuring the fluorescence of Indo-1 as described previously (20) with minor changes. The intracellular calcium levels were calculated as described (21) using a dissociation constant of 250 nM for Indo-1/Ca complex. In some cases, the cells were preincubated with 10 µM LTB receptor antagonist, LY223982, prior to the addition of agonists.

Gas Chromatography/Mass Spectrometry

The remainder of the HPLC system B fractions containing the hydrolyzed fatty acids were analyzed both by electron capture negative ion mass spectrometry and by electron impact ionization mass spectrometry using a Finnigan SSQ mass spectrometer (Finnigan Corp., San Jose, CA) interfaced with a capillary gas chromatograph column. For electron capture GC/MS, a portion of the fractions were derivatized as pentafluorobenzyl esters and trimethylsilyl ethers as described previously(22) . Prior to electron ionization GC/MS, samples were hydrogenated by bubbling hydrogen gas through a methanol solution of the sample for 30 min using rhodium adsorbed on alumina as the catalyst (1 mg). The samples were then derivatized as pentafluorobenzyl esters trimethylsilyl ethers.


RESULTS

Reverse phase HPLC separation of the oxidized 1-hexadecanoyl-2-arachidonoyl-GPCho revealed the presence of a large number of products. The major component in the mixture remained unreacted 1-hexadecanoyl-2-arachidonoyl-glycerophosphocholine, as indicated by the absorbance profile at 205 nm and elution at 78 min (Fig. 1A). The elution of conjugated trienes was indicated by absorbance at 270 nm (Fig. 1B), and many components absorbing at this wavelength were detected having significantly less lipophilicity than the starting material. The UV spectra of several components eluting between 44 and 54 min were suggestive of the characteristic vibronic UV absorption of conjugated trienes, as illustrated by the component eluting at 53 min in this HPLC separation (Fig. 1B, inset). The UV absorption profile at 235 nm (data not shown) revealed elution of several conjugated diene oxidized products in this same general area of the chromatogram.


Figure 1: Reverse phase HPLC separation of 1-hexadecanoyl-2-arachidonoyl-glycerophosphocholine (16:0a/20:4-GPC) oxidized by Cu/HO for 3 h at 37 °C (2 mM phospholipid in 50 mM PBS) and reduced with 1 mM SnCl. A, elution of components detected at 205 nm revealed the major component as unreacted starting material at 78 min. B, elution of components absorbing at 270 nm. Fraction 53 contained an oxidized phospholipid displaying the ultraviolet spectrum suggestive of a conjugated triene (inset). Other conjugated trienes eluted between 44 and 54 min. C, a major oxidized phospholipid component in fraction 53 yielded an ion at m/z 798.6 [M - 15] by electrospray ionization mass spectrometry that was collisionally activated and decomposed to yield fragment ions including the carboxylate anions for hexadecanoate (m/z 255) and the carboxylate anion for arachidonate plus two additional oxygen atoms (m/z 335).



Aliquots of each fraction collected during the HPLC separation were analyzed by electrospray ionization (ESI) mass spectrometry, which yields abundant [M - 15] ions for the lipid glycerophosphocholine molecular species(23) . For example, fraction 53 yielded abundant [M - 15] ions at m/z 798.6 and 814.7. These [M - 15] ions were then selected for subsequent tandem mass spectrometry. Collision-induced decomposition of the ion at m/z 798.6 from fraction 53 yielded two carboxylate anions at m/z 255 (characteristic for hexadecanoate) and m/z 335 (corresponding to the addition of two oxygen atoms to the arachidonate carboxylate anion) consistent with the carboxylate anion for a dihydroxyeicosatetraenoic acid (Fig. 1C). The ion at m/z 480 corresponded to the loss of the sn-2 substituent as a neutral ketene, confirming that the dioxygenated arachidonoyl moiety was esterified at sn-2. The ions at m/z 317 and 195 likely resulted from secondary fragmentation of m/z 335. Tandem mass spectrometric analysis of HPLC fractions between 44 and 54 min revealed elution of several dioxygenated eicosatetraenoic acids esterified at the sn-2 position of phosphatidylcholine.

Conjugated Triene Eicosanoids

The oxidized GPChos in the fractions between 44 and 54 min (Fig. 1A) were individually saponified and the liberated oxidized fatty acids were purified by the second reverse phase HPLC, system B. Components were observed in several fractions that had UV spectra with maximum absorption at 270 nm and vibronic bands 10 nm on either side at 260 and 280 nm, characteristic of a conjugated triene (Table 1). Each HPLC fraction (system B) was tested for its ability to elicit an increase in intracellular calcium from human polymorphonuclear leukocytes loaded with the fluorescent dye Indo-1 to screen for components with biological activity. HPLC separation of the free acids liberated from phospholipid fraction 53 (system A) is shown in Fig. 2A with the elution of a single component at 15.3 min (RRI = 2.54) absorbing at 270 nm (Fig. 2A, inset). The 0.5-ml fraction collected between 15 and 15.5 min was also found to have the highest level of activity in elevating intracellular calcium in the human neutrophil (Fig. 2B). Other closely eluting molecules maximizing in adjacent fractions were also present in this sample; however, these components did not have the characteristic UV chromophore of a conjugated triene (data not shown) but may have biological activity.




Figure 2: Reverse phase HPLC of the free acids obtained following saponification of the oxidized phospholipids in fraction 53 by gradient system B (see ``Experimental Procedures''). A, elution of components absorbing at 270 nm. A single component eluted at 15.3 min, which yielded the ultraviolet absorption spectrum of the conjugated triene (inset). B, equal aliquots of each half-minute fraction collected during the HPLC run were taken to dryness, dissolved in Ca/Mg free Hanks' balanced salt solution containing 0.05% bovine serum albumin and added to neutrophils previously loaded with Indo-1 (1 µM). The increase in [Ca] was calculated as described (21) .



Negative ion ESI/MS of the HPLC fractions (system B) containing conjugated triene free acids consistently revealed [M - H] ions at m/z 335, consistent with the carboxylate anion expected for dioxygenated arachidonic acid. Collision-induced decomposition of m/z 335 from these fractions yielded numerous product ions that were similar but often not identical to those observed following collision-induced decomposition of LTB (data not shown). Collision-induced decomposition of m/z 335 from the component eluting at 15.3 min (Fig. 2A) yielded the MS/MS spectrum shown in Fig. 3A with characteristic ions at m/z 59, 129, 195, and 317, all of which are also observed upon collision-induced decomposition of m/z 335 from LTB, 6-trans-LTB, and 6-trans-12-epi-LTB. This collision-induced decomposition mass spectrum differed significantly from that of other dihydroxy eicosanoids such as 8,15-, 5,6-, or 5,15-dihydroxyeicosatetraenoic acid isomers (data not shown). This mass spectral data was consistent with a 20-carbon fatty acid containing four double bonds and two hydroxyl substituents. The covalent backbone of the molecule was established following catalytic reduction of this metabolite using hydrogen and Rh/AlO followed by derivatization to the pentafluorobenzyl ester trimethylsilyl ether. The electron ionization mass spectrum (Fig. 3B) clearly revealed the presence of a saturated 20-carbon fatty acid derivative with two hydroxyl groups as trimethylsilyl ethers. The -cleavage ions m/z 555 and 215 supported assignment of a 12-hydroxy substituent, and m/z 369 and 401 supported assignment of a 5-hydroxy substituent(24) . A conjugated triene could only exist between the hydroxyl substituents at carbon atoms 5 and 12, placing the triene at carbons 6, 8, and 10. While the position of an isolated double bond at carbon 14 was not unambiguously assigned, this was the original position of the -6 double bond in arachidonic acid and this portion of the molecule was likely not altered by the oxidation process. The structure of this free radical product was thus established as 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid, a B-isoleukotriene. The oxidized phospholipid from which this dihydroxyeicosanoid was obtained was therefore 1-hexadecanoyl-2-[5,12-dihydroxy-6,8,10,14-eicosatetraenoyl]glycerophosphocholine (see Fig. SI).


Figure 3: A, tandem mass spectrometry of m/z 335, the major ion obtained by electrospray ionization of HPLC fraction (system B) (RRI = 2.54) eluting between 15 and 15.5 min (Fig. 2). B, electron ionization mass spectrum of the major component obtained following catalytic reduction and derivatization to the pentafluorobenzyl ester trimethylsilyl ethers obtained by GC/MS. This mass spectrum was indicative of derivatized 5,12-dihydroxyeicosanoic acid.




Figure SI: Scheme I.



Pharmacological Activity of B-Isoleukotrienes

As shown in Table 1, several conjugated triene eicosanoids were products of the free radical oxidation of 1-hexadecanoyl-2-arachidonoyl-GPCho. Several of these eicosanoids were found to stimulate an increase in intracellular free calcium ion in the human neutrophil. The absolute quantity used in the neutrophil assay differed for each sample since an equal proportion (16%) of each HPLC fraction was tested for biological activity and the absolute yield of each eicosanoid free radical product varied. In order to compare activities in the absence of complete dose-response curves, the biological activity in Table 1is expressed as the natural logarithm of the increase in intracellular calcium concentration (nM) per nanomolar concentration of eicosanoid tested. Some compounds displayed no activity in this assay. For example, the component with the HPLC relative retention index at 1.66 elicited no increase in intracellular free calcium ion when tested at a concentration of 28.2 nM (54 pmol). In contrast, the component that eluted with a relative retention index of 1.77 caused an increase of 626 nM [Ca] when tested with 38 pmol.

The response of Indo-1-labeled neutrophils to LTB (7 pmol) and the isolated isoleukotriene with an RRI = 1.86 (68 pmol) is shown in Fig. 4. Both compounds elicited a large increase in free intracellular calcium within the human neutrophil, although LTB was more than 10-fold more potent in this response. In contrast, the dual lipoxygenase product (5S,12S)-dihydroxyeicosatetraenoic acid in much larger quantity (90 pmol) elicited only a 43 nM increase in intracellular free calcium ion (data not shown).


Figure 4: Increase in fluorescence in human neutrophils containing Indo-1 following addition of B-isoleukotriene (final concentration, 34 nM) with HPLC relative retention index of 1.86 and LTB (final concentration, 3.4 nM). Following addition of LY223982 (10 µM), the same agonists were tested.



Further investigation of the pharmacologic effect of leukotrienes on the human neutrophil revealed that elevation of intracellular calcium ion could be blocked by administration of 10 µM LTB receptor antagonist LY223982(27) . As shown in Fig. 4, both responses from the component with relative retention index = 1.86 and LTB were completely attenuated by the LTB receptor antagonist LY223982. The LTB receptor antagonist also blocked the biological response elicited by eicosanoids with relative retention index of 2.54 and 1.77 (data not shown).

There was sufficient quantity of the isoleukotriene eluting with a relative retention index of 2.54 (Fig. 2A) for a dose-response study (Fig. 5). An EC of 30 nM was calculated for this eicosanoid product. This is approximately 100-fold less than that observed for LTB itself, which has an EC of 0.3-1 nM(25, 26) .


Figure 5: Dose-response curve for the elevation of intracellular free calcium caused by the B-isoleukotriene free acid eluting between 15 and 15.5 min in Fig. 2(RRI = 2.54). The calculated EC is approximately 30 nM.




DISCUSSION

Free radical oxidation of arachidonic acid esterified to glycerophospholipids is known to result in a host of oxidized intermediates. The recent discovery of the isoprostanes as free radical oxidation products of arachidonic acid and arachidonate-containing glycerophospholipids has emphasized that complex rearrangements of intermediate peroxy radical or hydroperoxides, formed as initial oxidation products, can take place. Described here is a new family of free radical-generated eicosanoids derived from arachidonoyl phospholipids. Several dihydroxy eicosanoids were observed, including several that contain a conjugated triene structural feature similar to that observed in the enzymatic products of 5-lipoxygenase. Detailed structural studies of an abundant, biologically active component (RRI = 2.54) revealed this eicosanoid to be a 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid. Therefore, we have termed this conjugated triene dihydroxy eicosanoids as a ``B-isoleukotriene'' as a free radical product of lipid peroxidation that resembles enzymatically produced LTB.

Several free radical mechanisms are possible by which such dihydroxy-conjugated trienes could be formed from arachidonic acid esterified to phospholipids. It is most likely that two separate radical abstraction events removing the bisallylic hydrogen atoms on carbon atoms 7 and 10 occurred and the addition of molecular oxygen resulted at carbon atoms 5 and 12 of the arachidonic acid backbone. One interesting possibility is an intermediate formation of a leukotriene A-like structure as a non-free radical intermediate present in the phospholipid. Hydrolysis of such a conjugated triene epoxide with water would yield isoleukotrienes as 5,12-dihydroxyeicosatetraenoic acids.

Several B-isoleukotrienes were found to be potent agonists stimulating the elevation of intracellular free calcium ion in the human neutrophil. Furthermore, this action could be blocked by the LTB receptor antagonist LY223982(27) . While the potency of the B-isoleukotriene that was studied in greatest detail (RRI = 2.54) was found to be somewhat less than that for LTB itself, it is similar to that found for other chemotactic substances such as the peptide fMLP(28, 29, 30) . This B-isoleukotriene and others described here, if formed in vivo, would have sufficient potency to play an important role in activating or priming neutrophils for a respiratory burst or priming neutrophils for leukotriene production by the 5-lipoxygenase pathway. Such oxidized products of arachidonate formed in membrane glycerophospholipids as a result of lipid peroxidation could be released as free acids (31) and activate nearby cells. As such, these isoleukotrienes would serve as mediators of tissue response to lipid peroxidative events.

A number of LTB isomers have been synthesized and studied as competitive substrates for the LTB receptor(32, 33, 34) , as well as for biological activity including causing an elevation of intracellular calcium (25, 35) and chemotaxis(33, 34, 36, 37, 38) . A wide variation in activity was observed for such isomers, suggesting certain structural features of LTB are important for binding and biological activity, which include a cis configuration of the double bond at carbon-6 and stereochemistry of the 12-hydroxyl substituent. The geometry of the double bonds in the conjugated triene moiety is also quite important for receptor recognition and it is noteworthy that the trans, cis, trans configuration of the double bonds at carbons 6, 8, and 10 confers tighter binding than those isomers having the all trans configuration in the conjugated triene moiety(39) . However, many of the synthetic isomers possess profound activity in many systems. The exact stereochemistry of the biologically active B-isoleukotrienes is currently under investigation.

B-Isoleukotrienes are a family of free radical-generated eicosanoids derived from arachidonoyl glycerophospholipids. These free radical products of lipid peroxidation resemble enzymatically produced LTB in both structure and biological activity. As such they could serve as lipid mediators of cellular free radical damage in tissues exerting an effect by way of the LTB receptor.


FOOTNOTES

*
This work was supported, in part, by Grant HL34303 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: National Jewish Center for Immunology and Respiratory Medicine, 1400 Jackson St., Denver, CO 80206.

The abbreviations used are: GPCho, glycerophosphocholine; PBS, phosphate-buffered saline; HPLC, high performance liquid chromatography; ESI, electrospray ionization; MS, mass spectrometry; LTB, leukotriene B; GC, gas chromatography; RRI, relative retention index.


REFERENCES
  1. Pryor, W. A. (1986)Annu. Rev. Physiol. 48, 657-667 [CrossRef][Medline] [Order article via Infotrieve]
  2. Britton, R. S., and Bacon, B. R.(1994)Hepatogastroenterology 41, 343-348 [Medline] [Order article via Infotrieve]
  3. Halliwell, B. (1991)Am. J. Med.91,14S-22S [Medline] [Order article via Infotrieve]
  4. Jaeschke, H.(1991) Chem. Biol. Interact. 79, 115-136 [CrossRef][Medline] [Order article via Infotrieve]
  5. Halliwell, B., and Gutteridge, J. M. C. (1989) Free Radicals in Biology and Medicine, pp. 416-508, Oxford University Press, Oxford, United Kingdom
  6. Tarr, M., and Samson, F. (eds) (1993) Oxygen Free Radical in Tissue Injury, Birkhauser, Boston
  7. Floyd, R. A., and Carney, J. M.(1992)Ann. Neural.32,S22-S27
  8. Stadtman, E. R. (1990)Free Radical Biol. Med. 9, 315-325 [CrossRef][Medline] [Order article via Infotrieve]
  9. Halliwell, B., and Gutteridge, J. M. C. (1989) Free Radicals in Biology and Medicine, pp. 188-276, Oxford University Press, Oxford
  10. Esterbauer, H., Schaur, R. J., and Zollner, H.(1991)Free Radicals Biol. Med. 11, 81-128 [CrossRef][Medline] [Order article via Infotrieve]
  11. Kneepkens, C. M., Lepage, G., and Roy, C. C.(1994)Free Radicals Biol. Med. 17, 127-160 [CrossRef][Medline] [Order article via Infotrieve]
  12. Shimizu, T., Kondo, K., and Hayaishi, O.(1981)Arch. Biochem. Biophys. 206,271 [Medline] [Order article via Infotrieve]
  13. Basu, A., and Marnett, L.(1984)Carcinogenesis4,331
  14. Morrow, J. D., Hill, K. E., Burk, R. F., Nammour, T. M., Badr, K. F., and Roberts, L. J. (1990)Proc. Natl. Acad. Sci. U. S. A. 87, 9383-9387 [Abstract]
  15. Morrow, J. D., Minton, T. A., Mukundan, C. R., Campbell, M. D., Zackert, W. E., Daniel, V. C., Badr, K. F., Blair, I. A., and Roberts, L. J., II(1994) J. Biol. Chem. 269, 4317-4326 [Abstract/Free Full Text]
  16. Kayganich-Harrison, K. A., Rose, D. M., Murphy, R. C., Morrow, J. D., and Roberts, L. J. (1993)J. Lipid Res. 34, 1229-1235 [Abstract]
  17. Morrow, J. D., Minton, T. A., and Roberts, L. J., II(1992)Prostaglandins 44, 155-163 [CrossRef][Medline] [Order article via Infotrieve]
  18. Kang, K. H., Morrow, J. D., Roberts, L. J., Newman, J. H., and Banerjee, M.(1993) J. Appl. Physiol. 74, 460-465 [Abstract]
  19. Halliwell, B., and Gutteridge, J. M.(1984)Biochem. J. 219, 1-14 [Medline] [Order article via Infotrieve]
  20. Powell, W. S., Gravel, S., MacLeod, R. J., Mills, E., and Hashefi, M.(1993) J. Biol. Chem. 268, 9280-9286 [Abstract/Free Full Text]
  21. Grynkiewicz, G., Poenie, M., and Tsien, R. Y.(1985)J. Biol. Chem. 260, 3440-3450 [Abstract]
  22. Wheelan, P., Zirrolli, J. A., and Murphy, R. C.(1995)J. Am. Soc. Mass Spectrom. 6, 40-51 [CrossRef]
  23. Kerwin, J. L., Tuininga, A. R., and Ericsson, L. H.(1994)J. Lipid Res. 35, 1102-1114 [Abstract]
  24. Murphy, R. C. (1993) Handbook of Lipid Research: Mass Spectrometry of Lipids, pp. 106-108, Plenum Press, New York
  25. Kobayashi, Y., Shimazaki, T., Kawajiri, K., Shimizu, T., Seyama, Y., and Sato, F. (1994)Biochim. Biophys. Acta 1215, 280-284 [Medline] [Order article via Infotrieve]
  26. Seya, A., Terano, Y., Tamura, S., and Yoshida, S.(1988)Prostaglandins Leukotrienes Essent. Fatty Acids 34, 37-43 [Medline] [Order article via Infotrieve]
  27. Jackson, W. T., Boyd, R. J., Froelich, L. L., Mallett, B. E., and Gapinski, D. M.(1992) J. Pharmacol. Exp. Ther. 263, 1009-1014 [Abstract]
  28. White, J. R., Naccache, P. H., Molski, T. F., Borgeat, P., and Sha'afi, R. I. (1983)Biochem. Biophys. Res. Commun. 113, 44-50 [Medline] [Order article via Infotrieve]
  29. Omann, G. M., Traynor, A. E., Harris, A. L., and Sklar, L. A.(1987)J. Immunol. 138, 2626-2632 [Abstract/Free Full Text]
  30. Lazzari, K. G., Proto, P. J., and Simons, E. R.(1986)J. Biol. Chem. 261, 9710-9713 [Abstract/Free Full Text]
  31. McLean, L. R., Hagaman, K. A., and Davison, W. S.(1993)Lipids 28, 505-509 [Medline] [Order article via Infotrieve]
  32. Leblanc, Y., Fitzsimmons, B. J., Charleson, S., Alexander, P., Evans, J. F., and Rokach J.(1987)Prostaglandins 33, 617-625 [CrossRef][Medline] [Order article via Infotrieve]
  33. Bomalaski, J. S., and Mong, S.(1987)Prostaglandins 33, 855-867 [Medline] [Order article via Infotrieve]
  34. Soyombo, O., Spur, B. W., Soh, C., and Lee, T. H.(1993)Eur. J. Biochem. 218, 59-66 [Abstract]
  35. Goldman, D. W., Gifford, L. A., Olson, D. M., and Goetzl, E. J.(1985)J. Immunol. 135, 525-530 [Abstract/Free Full Text]
  36. Palmblad, J., Malmsten, C. L., Uden, A. M., Radmark, O., Engstedt, L., and Samuelsson, B. (1981)Blood 58, 658-661 [Abstract]
  37. Lewis, R. A., Goetzl, E. J., Drazen, J. M., Soter, N. A., Austen, K. F., and Corey, E. J. (1981)J. Exp. Med. 154, 1243-1248 [Abstract]
  38. Dahinden, C. A., Clancy, R. M., and Hugli, T. E.(1984)J. Immunol. 133, 1477-1482 [Abstract/Free Full Text]
  39. Lee, T. H., Mencia-Huerta, J.-M., Shih, C., Corey, E. J., Lewis, R. A., and Austen, K. F.(1984)J. Biol. Chem. 259, 2383-2389 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.